A leading Australian drug reformulating company, seeking to make meaningful differences to patient care globally.
Reliis’ approach to drug development reduces the time and cost compared to new drug discovery.
Reliis partners with leading Australian clinicians, to identify unmet clinical needs that can be solved by reformulating existing off-patent medications.
Reliis has a highly experienced Board and management team. Our Scientific Advisory Board comprises leading clinicians and clinical researchers with an impressive track record in implementing change to clinical care.
Reliis’ unique approach to drug development allows for an accelerated pathway to registration and commercialisation compared to the traditional pharma model.
Reliis’ pipeline comprises reformulated products with global significance.